Revelation Biosciences, Inc. Announces Financial Results For the Three and Nine Months Ended September 30, 2026
Revelation Biosciences reported a Q3 2026 net loss of $3.3 million ($5.92 per share) versus $1.9 million a year ago, with operating expenses rising to $3.4 million from $1.9 million as the Gemini program scales toward its Phase 2/3 TITAN study in acute kidney injury. The company ended the quarter with $9.1 million in cash, down from $10.7 million at year-end, and says current cash funds operations only into the second quarter of 2027.
Key figures
- Tam
- $94 billion
- Cash
- 9121630
- Runway
- into the second quarter of 2027
- Opex q3 2026
- 3383576
- Cash dec 2025
- 10700331
- Net loss 9m 2026
- 9647948
- Net loss q3 2025
- 1907176
- Net loss q3 2026
- 3315513
- Rd expense q3 2026
- 1512898
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.